Catalogo dei prodotti della ricerca

NATONI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 174
AS - Asia 134
EU - Europa 112
AF - Africa 5
Totale 425
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 172
SG - Singapore 100
IT - Italia 60
DE - Germania 23
IN - India 22
RU - Federazione Russa 10
CN - Cina 8
EG - Egitto 5
GB - Regno Unito 4
IE - Irlanda 3
JP - Giappone 3
SE - Svezia 3
BE - Belgio 2
BY - Bielorussia 2
CA - Canada 2
FI - Finlandia 2
AT - Austria 1
ID - Indonesia 1
LU - Lussemburgo 1
LV - Lettonia 1
Totale 425
Salva come PNG Salva come JPEG
Città #
Singapore 75
Santa Clara 63
Rome 25
Ashburn 24
Pune 17
Boardman 15
Moscow 8
Milan 5
Turin 5
New York 4
Al Mansurah 3
Chennai 3
Dublin 3
Brussels 2
Calgary 2
Craigavon 2
Florence 2
Keams Canyon 2
Lappeenranta 2
Minsk 2
Romola 2
Tokyo 2
Villongo 2
West Jordan 2
Agawam 1
Bari 1
Brescia 1
Chiswick 1
Dallas 1
Danville 1
Delhi 1
Hagen 1
Hartford 1
Hounslow 1
Houston 1
Jakarta 1
Los Angeles 1
Miami 1
Phoenix 1
Reggio Emilia 1
Shimla 1
Springfield 1
St. Petersburg 1
Verona 1
Xiamen 1
Totale 293
Salva come PNG Salva come JPEG
Nome #
Sialylation regulates migration in chronic lymphocytic leukemia 40
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study 21
P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY 16
PSGL-1 decorated with sialyl Lewisa/x promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement 15
A 13-Glycosylation Gene Signature in Multiple Myeloma Can Predicts Survival and Identifies Candidates for Targeted Therapy (GiMM13) 14
Novel kinase inhibitors afuresertib and pim447 are active in a predictive myeloma in vivo model, and a crispr genome-wide screening approach identifies biomarkers determining susceptibility 14
Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma 14
Combination targeting of sialylation and the proteasome inhibits tumor growth and increases survival in a humanized mouse multiple myeloma model 12
CD38(low) Natural Killer Cells Transiently Expressing CD16(F158V) m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide 12
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment 11
iCARE-2 fellowship 11
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models 11
Engineering CD38 low natural killer cells to transiently express CD16 (f158v) m-RNA enhances the cytotoxic potential of daratumumab against multiple myeloma with minimal NK cell fratricide 11
A high through-put screen for small molecules modulating MCM2 phosphorylation identifies Ryuvidine as an inducer of the DNA damage response 11
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis 10
Chronic nitric oxide exposure induces prostate cell carcinogenesis, involving genetic instability and a pro-tumorigenic secretory phenotype 10
Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells 10
The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia 10
E-Selectin Ligand Expression Increases with Progression of Myeloma and Induces Drug Resistance in a Murine Transplant Model, Which Is Overcome By the Glycomimetic E-Selectin Antagonist, GMI-1271 10
Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment 9
A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization 9
Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study 9
Low dose cyclophosphamide potentiates the anti-myeloma activity of daratumumab through augmentation of macrophage-induced ADCP 9
Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells 9
Targeting Siglec-7: A Novel Immunotherapeutic Approach to Potentiate the Cytotoxic Functions of Natural Killer Cells Against Multiple Myeloma 8
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity 8
Treatment of proliferative disorders with a death receptor agonist 8
Novel kinase inhibitors afuresertib and PIM447 are active alone and in combination with standard therapies, respectively, in a predictive MM in vivo model, and a CRISPR genome-wide screening approach identifies clinically-relevant biomarkers determining susceptibility to these therapeutic strategies 8
Patient Data Supports the Rationale of Low Dose Cyclophosphamide to Potentiate the Anti-Myeloma Activity of Daratumumab through Augmentation of Macrophage-Induced ADCP 8
Targeting siglec-7: a novel immunotherapeutic approach to potentiate the cytotoxic functions of natural killer cells against multiple myeloma 8
Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP 7
TARGETING SIGLEC-7: A NOVEL IMMUNOTHERAPEUTIC APPROACH TO POTENTIATE THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA 7
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271 7
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis 7
Multiple Myeloma Cells Express Functional E-Selectin Ligands Which Can be Inhibited Both in-Vitro and in-Vivo Leading to Prolongation of Survival in a Murine Transplant Model 6
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2 6
Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor 6
PHA767491, a Dual Cdc7/CDK9 Inhibitor, with Potential to Target Both Proliferation and Survival in CLL 6
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14) 5
Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor 5
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma 5
Calicivirus translation initiation requires an interaction between VPg and eIF 4 E 5
Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors 5
Platelets Preferentially Bind to Myeloma Cells Bearing Sialofucosylated Structures and Protect Them from Natural Killar Cell-Mediated Cytotoxicity 5
Targeting Selectins and Their Ligands in Cancer 5
Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells 4
Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo 4
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model 4
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide 4
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses 4
Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells 4
Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model 4
Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment 4
Targeting the Pim kinases in multiple myeloma 4
Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants 3
Targeting AML through DR4 with a novel variant of rhTRAIL 3
NOXA contributes to the sensitivity of PERK-deficient cells to ER stress 3
Isosteric replacement of the Z-enone with haloethyl ketone and E-enone in a resorcylic acid lactone series and biological evaluation 3
The mitochondrial pathway of apoptosis is triggered during feline calicivirus infection 3
Totale 494
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 103
selected - selezionate 0
volume - volumi 0
Totale 5.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023107 0 0 0 0 0 0 0 0 67 8 32 0
2023/2024201 8 20 6 13 16 41 12 1 4 22 20 38
2024/2025186 3 20 20 47 77 17 2 0 0 0 0 0
Totale 494